Equity, Bottom-up Analyst, Investics Research

Sameer Taneja

A buy-side analyst with over 18 years of experience investing in Asian markets and specializing in the mid-small cap space, emphasizing value investing in companies with good free cash flows/dividends and long-term holding horizons. 
Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd. It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity, Bottom-up Analyst

Perfect Medical (1830 HK): Firming Up Outlook For FY27, Improving HK Retail Beneficiary

Perfect Medical (1830 HK): Green Shoots Emerging After A Disastrous FY25

Perfect Medical (1830 HK): Cost-Cutting Initiatives Bearing Fruit, Demand Recovery Needs Monitoring

Medical Beauty Plays in Hong Kong: Perfect/Water Oasis and Flameglow: A Better Retail Environment?

Water Oasis (1161 HK) - Getting Silly, Cash Now 118% of Market Capitalization

Investics Research

It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity Bottom-up Research

Equity Bottom-Up

Perfect Medical Health Management / Equity Bottom-Up

Perfect Medical Health Management (1830 HK)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/perfect-medical-health-management-limited" target="_blank" data-smartkarma-citation="entities:3639:1" rel="noopener">Perfect Medical Health Management (1830 HK)</a>  reported FY26 revenue of HKD 962.3mn (-14.7% YoY) and net profit attributable of HKD 178.7mn (-13.6% YoY), with improving H2 results on stabilizing sentiment. </li>
<li>The story is the H2 inflection, where revenue fell 6.1% YoY (vs -21.7% in H1), while H2 net profit rose 27.1% period-on-period to HKD 83.9mn, driven by cost cuts.</li>
<li>Debt-Free, cash-rich (~HKD 523mn cash + investments) and holding a 100%+ payout for an 11th straight year (FY26 payout 102.8%), the stock offers a ~12.6% yield at ~8.2x P/E.</li>
</ul>



Perfect Medical Health Management (1830 HK)  reported FY26 revenue of HKD 962.3mn (-14.7% YoY) and net profit attributable of HKD 178.7mn (-13.6% YoY), with improving H2 results on stabilizing sentiment. 
The story is the H2 inflection, where revenue fell 6.1% YoY (vs -21.7% in H1), while H2 net profit rose 27.1% period-on-period to HKD 83.9mn, driven by cost cuts.
Debt-Free, cash-rich (~HKD 523mn cash + investments) and holding a 100%+ payout for an 11th straight year (FY26 payout 102.8%), the stock offers a ~12.6% yield at ~8.2x P/E.


Perfect Medical (1830 HK): H2 Turnaround as Cost Discipline Lifts Margins; Watch the Demand Recovery